Current Report Filing (8-k)
15 November 2021 - 08:34PM
Edgar (US Regulatory)
0001477845
false
0001477845
2021-11-15
2021-11-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
November 15, 2021
ANNOVIS BIO, INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-39202
|
|
26-2540421
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312
(Address of Principal Executive Offices, and
Zip Code)
(610) 727-3913
Registrant’s Telephone Number, Including
Area Code
Not
Applicable
(Former Name or Former Address, if Changed Since
Last Report)
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Common Stock, par value $0.0001 per share
|
ANVS
|
NYSE American
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communication pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 3.01
|
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
On November 15, 2021, Annovis Bio, Inc. (the
“Company”) announced that the New York Stock Exchange (“NYSE”) had approved the transfer of listing of the
common stock, $0.0001 par value per share (the “Common Stock”) of the Company from the NYSE American to the NYSE and
that, effective November 18, 2021, the Company’s Common Stock will cease trading on the NYSE American and will commence
trading on the NYSE under the symbol “ANVS” and until the close of trading
on November 17, 2021, the Common Stock will continue to trade on the NYSE American under the symbol “ANVS.”
Item 7.01
|
Regulation FD Disclosure.
|
On November 15, 2021, the Company issued a press
release announcing the transfer of listing from the NYSE American to the NYSE. A copy of the Press Release is attached to this Current
Report on Form 8-K as Exhibit 99.1.
The information in this Item 7.01, Item 9.01 and
Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
or otherwise subject to the liability of such section, nor shall it be deemed incorporated by reference in any filing of the Company under
the Securities Act of 1933 or the Securities Exchange Act of 1934, regardless of any general incorporation language in such filing, unless
expressly incorporated by specific reference in such filing.
Item 9.01
|
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ANNOVIS BIO, INC.
|
|
|
|
Date: November 15, 2021
|
By:
|
/s/ Jeffrey McGroarty
|
|
|
Name: Jeffrey McGroarty
|
|
|
Title: Chief Financial Officer
|
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
Von Mär 2023 bis Mär 2024